This study provides evidence that markers of tumour biology, specifically vasculature immaturity (% IMM) and tumour epithelial 8-oxo-dG in the tissue and serum IL6 and IL8 stratify survival outcome of mCRC patients on bevacizumab treatment. The gene discussed is IL6; the disease is neoplasm.